DXVX announced on the 23rd that it has completed a joint research clinical trial for the development of microbiome-based metabolic disease therapeutics.
DXVX has been conducting joint research with Cori Group and Italy's Gemelli Hospital to develop microbiome-based therapeutics for metabolic diseases such as obesity and diabetes. Recently, they completed a clinical trial observing changes in the gut microbiome of patients with diabetes and obesity and are currently developing protocols for follow-up studies.
DXVX plans to commercialize research outcomes across a wide range of fields, including the development of microbiome-based metabolic disease therapeutics and biomarkers, diagnostics, and medical data. In particular, microbiome therapeutics are expected to minimize side effects while maintaining the body's natural microbial balance, thereby alleviating the high costs and long-term treatment burdens associated with existing therapies.
Since 2020, DXVX has been conducting clinical trials at Agostino Gemelli University Hospital in Rome, Italy, observing changes in the gut microbiome of patients with type 2 diabetes and obesity. The clinical study involved a cohort of approximately 150 individuals, including type 2 diabetes patients, obese patients, patients with both conditions, and healthy adults. They are conducting metagenomic analysis together with the research team led by Professor Lorenza Putignani, a leading expert in microbiome research in Italy, and aim to maximize the therapeutic potential for metabolic diseases by collecting multi-omics data through future metabolomics analysis to discover biomarkers.
The main goal of this research is to analyze the composition and changes of the microbiome in metabolic disease patients to discover biomarkers suitable for metabolic diseases and develop therapeutics based on these biomarkers. Additionally, they plan to secure innovative biomarkers that can be used for the development of microbiome-based health functional foods as well as for diagnosis and prognosis monitoring.
Han Seong-jun, CEO of Cori Group and CTO of DXVX, stated, “This clinical data is expected to accelerate the development of microbiome-based metabolic disease therapeutics and bring significant changes to the treatment of metabolic diseases in the future.”
Meanwhile, the type 2 diabetes market is expected to grow at a compound annual growth rate (CAGR) of 10.94% from 2022 to 2027, reaching a market size of approximately $39.3 billion. The incidence of diabetes is rapidly increasing among children and adolescents, emphasizing the importance of early diagnosis and treatment. The obesity therapeutics market is also projected to grow from $5.7 billion in 2022 to $15.1 billion in 2032, with an expected annual growth rate of 10.6%.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
